Effects of anaesthetics and trauma on stimulated gastric acid secretion in chronic fistula dogs.
1. The present study was undertaken to determine whether various anaesthetic agents affect canine gastric acid secretion independently of other experimental variables. 2. Acid secretory output was determined in dogs with chronic fistulae, by administering sedating doses of anaesthetics commonly used for studying gastric secretory mechanisms in laboratory animals. 3. The anaesthetic agents inhibited gastric acid secretion. As the inhibitory effect of the mixture of anaesthetics was pronounced, an attempt was made to study the effect of each individual anaesthetic agent separately. 4. Acetopromazine was given to sedate dogs. Although it has a long duration of action, it only had a transient inhibitory action on gastric acid secretion of 15-30 min duration. Moreover the drug reduced pentagastrin-stimulated secretion, but had no effect on histamine-stimulated secretion. 5. Thiopentone sodium given with acetopromazine produced a mild inhibitory effect on histamine-stimulated secretion for 45 min, but produced a more pronounced and sustained inhibitory effect on pentagastrin-stimulated secretion. 6. Trilene significantly inhibited both histamine- and pentagastrin-stimulated secretion. The effect on the latter was more pronounced and sustained. 7. Trauma had no significant effect on histamine-stimulated secretion, but showed a slight inhibitory effect on pentagastrin-stimulated secretion. 8. Experiments to study gastric secretory mechanisms and antisecretory drugs should take account of the potential inhibitory effects of anaesthetics. Where possible, studies in conscious dogs with gastric fistulae are preferable to experiments on anaesthetized animals.
Bastaki
S M
SM
Department of Pharmacology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Waton
N G
NG
D000075:Acepromazine / Q000494:pharmacology; D000777:Anesthetics / Q000494:pharmacology*; D018681:Anesthetics, General / Q000494:pharmacology; D000818:Animals; D004285:Dogs; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006632:Histamine / Q000494:pharmacology; D006633:Histamine Antagonists / Q000494:pharmacology; D007262:Infusions, Intravenous; D008297:Male; D010418:Pentagastrin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013268:Stimulation, Chemical; D013874:Thiopental / Q000494:pharmacology; D014241:Trichloroethylene / Q000494:pharmacology; D014947:Wounds and Injuries / Q000378:metabolism*
D000777:Anesthetics; D018681:Anesthetics, General; D018492:Dopamine Antagonists; D006633:Histamine Antagonists; D014241:Trichloroethylene; D000075:Acepromazine; D006632:Histamine; D010418:Pentagastrin; D013874:Thiopental